Please find attached herewith Annual Secretarial Compliance Report for the year ended on March 31, 2026
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nectar Lifesciences has filed its annual Secretarial Compliance Report for FY 2025-26. The secretarial auditor Prince Chadha (P. Chadha & Associates) reviewed compliance with applicable SEBI regulations and found two deviations: (1) Delay in financial results submission under Regulation 33 — the Q4 and FY2025 results were not declared by the prescribed timeline; the Board meeting was held on May 30, 2025, beyond the deadline, and results were ultimately approved on July 7, 2025. A fine of ₹1.24 lakh was imposed by NSE and BSE. The management cited the CMD's illness and travel as the cause. (2) Failure to provide two working days' advance notice for the adjourned Board meeting under Regulation 29, resulting in a fine of ₹11,800. Both fines were paid and defaults rectified. The auditor notes one pending matter before the Supreme Court regarding Regulation 17(1A) for earlier fiscal years, which remains subjudice. Overall, the company reported compliance across all other areas including secretarial standards, policies, website maintenance, insider trading norms, and related party transactions.
The company has two regulatory lapses related to delayed financial disclosures and inadequate notice for board meetings, both resolved with fines. The matters are treated as non-recurring and closed by the exchanges. Investors should note the pending Supreme Court case on board composition for earlier years, though the current-year compliance record is largely clean.